DK560075A - Fremgangsmade til fremstilling af 15-substituerede 2 descarboxy-2-(tetrazol-5-yl)-11-desoxy-omega-pentanorprostaglandiner og mellemprodukter til anvendelse herved - Google Patents

Fremgangsmade til fremstilling af 15-substituerede 2 descarboxy-2-(tetrazol-5-yl)-11-desoxy-omega-pentanorprostaglandiner og mellemprodukter til anvendelse herved

Info

Publication number
DK560075A
DK560075A DK560075A DK560075A DK560075A DK 560075 A DK560075 A DK 560075A DK 560075 A DK560075 A DK 560075A DK 560075 A DK560075 A DK 560075A DK 560075 A DK560075 A DK 560075A
Authority
DK
Denmark
Prior art keywords
pentanor
descarboxy
desoxy
tetrazol
prostaglandins
Prior art date
Application number
DK560075A
Other languages
Danish (da)
English (en)
Inventor
M R Johnson
T K Schaaf
J F Eggler
J S Bindra
H-J E Hess
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of DK560075A publication Critical patent/DK560075A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/06—Saturated compounds having a carboxyl group bound to a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1896—Compounds having one or more Si-O-acyl linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4056—Esters of arylalkanephosphonic acids
    • C07F9/4059—Compounds containing the structure (RY)2P(=X)-(CH2)n-C(=O)-(CH2)m-Ar, (X, Y = O, S, Se; n>=1, m>=0)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK560075A 1974-12-11 1975-12-10 Fremgangsmade til fremstilling af 15-substituerede 2 descarboxy-2-(tetrazol-5-yl)-11-desoxy-omega-pentanorprostaglandiner og mellemprodukter til anvendelse herved DK560075A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/531,675 US3932389A (en) 1974-12-11 1974-12-11 2-Descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.omega.-pentanorprostaglandins

Publications (1)

Publication Number Publication Date
DK560075A true DK560075A (da) 1976-06-12

Family

ID=24118587

Family Applications (1)

Application Number Title Priority Date Filing Date
DK560075A DK560075A (da) 1974-12-11 1975-12-10 Fremgangsmade til fremstilling af 15-substituerede 2 descarboxy-2-(tetrazol-5-yl)-11-desoxy-omega-pentanorprostaglandiner og mellemprodukter til anvendelse herved

Country Status (24)

Country Link
US (1) US3932389A (ja)
JP (2) JPS5186465A (ja)
AR (1) AR222623A1 (ja)
BE (1) BE836563A (ja)
CA (1) CA1059122A (ja)
CH (2) CH614434A5 (ja)
CS (3) CS191960B2 (ja)
DD (2) DD129644A5 (ja)
DK (1) DK560075A (ja)
ES (1) ES443422A1 (ja)
FI (1) FI62289C (ja)
FR (1) FR2293927A1 (ja)
GB (2) GB1515415A (ja)
GR (1) GR58521B (ja)
HU (1) HU175278B (ja)
IE (1) IE42937B1 (ja)
IL (1) IL48637A (ja)
LU (1) LU73996A1 (ja)
NL (1) NL163509C (ja)
NO (1) NO145381C (ja)
NZ (1) NZ179503A (ja)
SE (2) SE415759B (ja)
YU (1) YU313775A (ja)
ZA (1) ZA757754B (ja)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4102894A (en) * 1975-11-19 1978-07-25 Pfizer Inc. 15-Substituted-ω-pentanorprostaglandins
US4035360A (en) * 1974-12-11 1977-07-12 Pfizer Inc. Magnesium salts of 2-descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-omega-pentanoprostaglandins
US3984400A (en) * 1975-10-21 1976-10-05 Pfizer Inc. 11-Desoxy-16-aryl-ω-tetranorprostaglandins
JPS5295670A (en) * 1976-02-04 1977-08-11 Pfizer 22decarboxyy225 tetrazoll55yl**11deoxyy omegaapentanolprostaglandine
US4342868A (en) * 1977-06-13 1982-08-03 Pfizer Inc. 2-Descarboxy-2-(tetrazol-5-yl)-16,16-dimethyl-17-(2-furyl)-ω-trisnorprostaglandin E2
US4404372A (en) * 1977-06-13 1983-09-13 Pfizer Inc. 15-Substituted-ω-pentanorprostaglandin derivatives
US4097601A (en) * 1977-08-26 1978-06-27 Pfizer Inc. Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins
JPS54119465A (en) * 1979-02-02 1979-09-17 Pfizer Intermediate for manufacturing 22decarboxyy 22*tetrasoll55yl**111deoxyyomegaapentanol prostaglandin
JPS54119464A (en) * 1979-02-02 1979-09-17 Pfizer Intermediate for manufacturing 22decarboxyy 22*tetrasoll55yl**111deoxyyomegaapentanol prostaglandin
US4336393A (en) * 1979-04-02 1982-06-22 The Upjohn Company 2-Decarboxy-2-tetrazolyl-13,14-dihydro-PG1 compounds
US4336372A (en) * 1979-04-02 1982-06-22 The Upjohn Company 2-Decarboxy-2-tetrazolyl-PG2 compounds
US4336371A (en) * 1979-04-02 1982-06-22 The Upjohn Company 2-Decarboxy-2-tetrazolyl-13,14-dihydro-PG2 compounds
US4336392A (en) * 1979-04-02 1982-06-22 The Upjohn Company 2-Decarboxy-2-tetrazolyl-PG1 compounds
JPS5991116U (ja) * 1982-12-09 1984-06-20 名倉　啓介 バツクル
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
AU7349298A (en) 1997-06-23 1999-01-04 Pfizer Inc. Prostaglandin agonists
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
US20020161026A1 (en) * 2000-11-07 2002-10-31 Paralkar Vishwas M. Combination therapies for the stimulation of bone growth
EP1420793A1 (en) * 2001-08-23 2004-05-26 Sucampo AG Method and composition for treatment of ocular hypertension and glaucoma
EP1490055A1 (en) * 2002-03-18 2004-12-29 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
US20030220377A1 (en) * 2002-05-08 2003-11-27 Richard Chesworth Indole compounds and their use as estrogen agonists/antagonists
US20040002524A1 (en) * 2002-06-24 2004-01-01 Richard Chesworth Benzimidazole compounds and their use as estrogen agonists/antagonists
US20050203086A1 (en) * 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
CA2632653C (en) * 2005-12-07 2014-11-04 Ramot At Tel Aviv University Ltd. Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof in the treatment of cancer
US9284274B2 (en) 2005-12-07 2016-03-15 Ramot At Tel-Aviv University Ltd. Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
US9284252B2 (en) 2009-06-09 2016-03-15 Sepal Pharma Ltd. Use of jasmonate ester derivatives for treating benign hyperproliferative skin disorders
BR112020016256A2 (pt) 2018-02-21 2020-12-15 AI Therapeutics, Inc. Terapia de combinação com apilimod e agentes gluta-matérgicos

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE788209A (fr) * 1971-09-01 1973-02-28 Pfizer Derives tetrazoyliques des prostaglandines naturelles

Also Published As

Publication number Publication date
GR58521B (en) 1977-10-29
NO145381B (no) 1981-11-30
CS191995B2 (en) 1979-07-31
FR2293927B1 (ja) 1979-02-23
FI753474A (ja) 1976-06-12
ES443422A1 (es) 1977-04-16
SE7907780L (sv) 1979-09-19
FI62289C (fi) 1982-12-10
YU313775A (en) 1982-06-30
JPS568035B2 (ja) 1981-02-20
CS191996B2 (en) 1979-07-31
GB1515415A (en) 1978-06-21
IE42937B1 (en) 1980-11-19
SE7513708L (sv) 1976-06-14
IL48637A (en) 1979-12-30
LU73996A1 (ja) 1976-11-11
NZ179503A (en) 1978-07-10
NO145381C (no) 1982-03-10
NL163509B (nl) 1980-04-15
JPS5186465A (en) 1976-07-29
IE42937L (en) 1976-06-11
AR222623A1 (es) 1981-06-15
NO754174L (ja) 1976-06-14
CS191960B2 (en) 1979-07-31
AU8736375A (en) 1977-06-02
DD129644A5 (de) 1978-02-01
FR2293927A1 (fr) 1976-07-09
JPS541711B2 (ja) 1979-01-27
HU175278B (hu) 1980-06-28
US3932389A (en) 1976-01-13
DD129648A5 (de) 1978-02-01
NL7514447A (nl) 1976-06-15
BE836563A (fr) 1976-06-11
SE415759B (sv) 1980-10-27
CA1059122A (en) 1979-07-24
CH614434A5 (ja) 1979-11-30
JPS52116471A (en) 1977-09-29
ZA757754B (en) 1976-11-24
FI62289B (fi) 1982-08-31
IL48637A0 (en) 1976-02-29
NL163509C (nl) 1980-09-15
CH612188A5 (ja) 1979-07-13
GB1515414A (en) 1978-06-21

Similar Documents

Publication Publication Date Title
DK560075A (da) Fremgangsmade til fremstilling af 15-substituerede 2 descarboxy-2-(tetrazol-5-yl)-11-desoxy-omega-pentanorprostaglandiner og mellemprodukter til anvendelse herved
AT341654B (de) Gelenkendoprothese
IT1051626B (it) Giunto omocinetico
DK142237C (da) Kontinuerlig fremgangsmaade til fremstilling af alkoxysilaner
AT335051B (de) Gelenkendoprothese
DK319277A (da) Hydroxysuccinimidestere fremgangsmade til fremstilling heraf og anvendelse heraf
DK144298C (da) Fremgangsmaade til fremstilling af alkyl-tert-butylethere
DK269175A (da) Fremgangsmade til fremstilling af d-phenylglycinamid og l-phenylglycin
SE429142B (sv) Fogkonstruktion
DK385475A (da) Fremgangsmade til fremstilling af secoprostaglandiner
DK222975A (da) Fremgangsmade til fremstilling af polysocyanater og disses anvendelse
DK273376A (da) Fremgangsmade til fremstilling af 11-desoxy-16-aryloxy-omega-pentanorprostaglandiner
DK141849C (da) Fremgangsmaade til fremstilling af slagseje vinylaromat-podecopolymere
DK121776A (da) Fremgangsmade til fremstilling af tricosen-(9) og heneicosen-(9)
DK184377A (da) Fremgangsmade til fremstilling af indazolyl-(4)-oxy-propanolaminer
DK206375A (da) Fremgangsmade til fremstilling af thiaprostaglandiner
DK583775A (da) Fremgangsmade til fremstilling af 3-fluorbenzodiazepiner
DK543875A (da) Fremgangsmade til fremstilling af hydroxyphenylacetonitriler
DK528475A (da) Fremgangsmade til fremstilling af tetramethylethylendiamin
DK559975A (da) Fremgangsmade til fremstilling af 15-substituerede 11-desoxy-omega-pentanorprostaglandiner og mellemprodukter til anvendelse herved
DK157137C (da) Fremgangsmaade til fremstilling af substituerede 3-methylencephamsulfoxider
DK137539C (da) Fremgangsmaade til fremstilling af 11beta-fluor-4-androsten-3-oner
DK263775A (da) Fremgangsmade til fremstilling af 9-thia-eller oxothia- og dioxothia-11,12-seco-prostaglandiner
DK593575A (da) Fremgangsmade til fremstilling af trichlorethylchlorformiat
GB1545633A (en) 11-deoxy substituted prostaglandins of the e and f series

Legal Events

Date Code Title Description
ATS Application withdrawn